Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2018-07

    • I-BET-762: A Selective BET Inhibitor for Epigenetic and I...

    2026-01-12

    I-BET-762: A Selective BET Inhibitor for Epigenetic and Inflammation Research

    Executive Summary: I-BET-762 (SKU B1498) is a potent and selective inhibitor of the bromodomain and extra-terminal domain (BET) family with nanomolar affinity (IC50: 32.5–42.5 nM; Kd: 50.5–61.3 nM) for the acetyl-lysine binding pocket of BET proteins (APExBIO). It operates by competitively displacing acetyl-lysine residues, exhibiting a unique 2:1 binding ratio, and shows no significant activity against non-BET bromodomain proteins (APExBIO). In preclinical models, I-BET-762 downregulates lipopolysaccharide (LPS)-inducible cytokine genes, resulting in marked anti-inflammatory effects in vivo (Fan et al., 2024). Recent studies confirm that I-BET-762 synergizes with ferroptosis inducers to enhance cancer cell death, highlighting its value in advanced cancer biology workflows (Fan et al., 2024). The compound is recommended for research targeting BET-mediated transcriptional regulation, inflammation, and cancer biology.

    Biological Rationale

    BET proteins (BRD2, BRD3, BRD4, BRDT) are epigenetic 'reader' proteins that recognize acetyl-lysine marks on histones and regulate gene transcription. Dysregulation of BET signaling is implicated in inflammation, cancer, and other diseases. BRD4, a key BET family member, modulates expression of genes controlling cell cycle, survival, and inflammatory response (Fan et al., 2024). Inhibiting BET proteins with small molecules such as I-BET-762 enables targeted modulation of pathological gene expression. I-BET-762 is designed as a selective epigenetic regulator with minimal off-target effects. Its anti-inflammatory action is mediated via suppression of LPS-inducible cytokines and chemokines in vivo and in vitro (APExBIO).

    Mechanism of Action of I-BET-762

    I-BET-762 functions as a highly selective BET bromodomain inhibitor by occupying the acetyl-lysine (AcK) binding pocket of BET proteins. The interaction occurs with high affinity (Kd: 50.5–61.3 nM) and is characterized by a 2:1 binding stoichiometry, reinforcing its selectivity (APExBIO). This competitive binding displaces acetyl-lysine residues, thus blocking BRD4 and related BET proteins from engaging with chromatin. The inhibition disrupts transcriptional coactivation complexes required for the expression of key inflammatory and oncogenic genes. Recent mechanistic studies further show that I-BET-762, like the structurally related JQ-1, leads to downregulation of ferroptosis suppressor protein 1 (FSP1) and accumulation of reactive oxygen species (ROS), enhancing sensitivity to ferroptosis inducers in multiple cancer cell lines (Fan et al., 2024).

    Evidence & Benchmarks

    • I-BET-762 binds BET proteins with nanomolar affinity (IC50: 32.5–42.5 nM; Kd: 50.5–61.3 nM) and does not significantly inhibit non-BET bromodomains (APExBIO).
    • BRD4 inhibition with I-BET-762 leads to significant ROS accumulation and downregulation of FSP1, increasing sensitivity to erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cells (Fan et al., 2024).
    • In mouse models, I-BET-762 downregulates LPS-induced cytokines and chemokines, demonstrating clear anti-inflammatory efficacy (APExBIO).
    • ChIP-seq data confirm that BRD4 binding at the FSP1 promoter is disrupted by I-BET-762, linking epigenetic modulation directly to ferroptosis pathway regulation (Fan et al., 2024).
    • Cell viability and cytotoxicity assays show reproducible, dose-dependent effects when I-BET-762 is integrated into proliferation and apoptosis workflows (Internal: Data-Driven Solutions).

    Applications, Limits & Misconceptions

    I-BET-762 is widely used for preclinical studies in epigenetic regulation, inflammation research, and cancer biology, particularly in the context of BET protein signaling pathway modulation. The compound is valuable in experiments requiring precise control of transcriptional activation driven by acetyl-lysine recognition. It also serves as a tool compound for dissecting ferroptosis mechanisms, especially in FSP1-dependent cancer models (Fan et al., 2024).

    This article extends the mechanistic insights described in "I-BET-762: Innovating BET Inhibition for Ferroptosis and Inflammation" by providing new evidence for direct disruption of FSP1 promoter binding via ChIP-seq. It also expands on practical workflow parameters beyond those in "I-BET-762: Practical Answers for BET Inhibition", with updated benchmarks from peer-reviewed studies. For a systems-biology perspective, see "I-BET-762: Next-Gen BET Inhibition in Ferroptosis and Inflammation", which this article clarifies by focusing on experimentally validated molecular endpoints.

    Common Pitfalls or Misconceptions

    • I-BET-762 is not active against non-BET bromodomain proteins; it should not be used to study unrelated bromodomain family members (APExBIO).
    • The compound is insoluble in water; use DMSO or ethanol (with ultrasound) to dissolve, at concentrations ≥21.19 mg/mL (DMSO) or ≥13.93 mg/mL (ethanol) (APExBIO).
    • Degradation risk in solution; prepare fresh aliquots or use promptly after dissolution to avoid loss of potency (APExBIO).
    • Not approved for clinical use; I-BET-762 is strictly for research purposes and not for diagnostic or therapeutic applications (APExBIO).
    • BET inhibition may have cell-line specific effects; transcriptional outcomes, especially on ferroptosis-related genes, can vary between model systems (Fan et al., 2024).

    Workflow Integration & Parameters

    I-BET-762 is supplied as a solid (molecular weight 423.9, C22H22ClN5O2) and should be stored at -20°C. For cell-based assays, dissolve in DMSO at concentrations ≥21.19 mg/mL or in ethanol (ultrasonicated) at ≥13.93 mg/mL. Avoid aqueous buffers for stock solutions. Add to culture media at working concentrations based on published IC50 values (typically 0.5–2 μM for cell assays) (Fan et al., 2024). Freshly prepare solutions before each use to maximize reproducibility.

    Integration into workflows includes cell viability, cytotoxicity, and transcriptomics assays for epigenetic regulation, inflammation, and ferroptosis studies. APExBIO recommends referencing the I-BET-762 product page for detailed storage and handling protocols. For scenario-driven experimental guidance and troubleshooting, see "I-BET-762 (SKU B1498): Data-Driven Solutions for BET Inhibition", which this dossier augments with updated peer-reviewed evidence.

    Conclusion & Outlook

    I-BET-762 remains a gold-standard BET inhibitor for research into epigenetic regulation and inflammatory/cancer pathways. Its selectivity and potency are well-documented. New evidence connects BET inhibition with modulation of ferroptosis, broadening its application scope in cancer biology. Future advances may refine its use in combination therapies or systems-biology approaches. For authoritative sourcing and technical support, APExBIO provides validated documentation for I-BET-762 (APExBIO).